All In Biotech

Drug Trial Radar · NCT04712032

Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates

A PHASE III, RANDOMISED CONTROLLED TRIAL ASSESSING THE VALUE OF INDOCYANINE GREEN IN THE LEAKAGE RATE OF COLORECTAL ANASTOMOSES

Last checked: Nov 19, 2026Latest source record: Jan 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 978 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

978

Planned (sponsor's estimate)

Start

Jul 1, 2020

Primary completion

Jul 1, 2022

Study completion Oct 1, 2022

Sponsor

Lead sponsor
Leiden University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Center Haaglanden; Catharina Ziekenhuis Eindhoven; Haga Hospital; Jeroen Bosch Ziekenhuis; Amphia Hospital; Alrijne Hospital; IJsselland Hospital
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anastomotic leakage (AL) is one of the major complications after gastrointestinal surgery. Compromised tissue perfusion at the anastomosis site increases the risk of AL. Indocyanine green (ICG) combined with fluorescent near infrared imaging has proven to be a feasible and reproducible application for real-time intraoperative quantification of the tissue perfusion and cohort studies showed reduced leakage rate. Unfortunately, these studies were not randomized. Therefore, we propose a nationwide randomized controlled trial to identify the value of ICG for AL in colorectal anastomosis.

Conditions

  • Colo-rectal Cancer
  • Crohn Disease
  • Resectable Colorectal Carcinoma

Interventions

  • ICG-guided bowel perfusion assessmentDrug

    ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 90-days Anastomotic Leakage (AL) rateTime frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Leiden University Medical Center

    Leiden, South Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.